This secondary analysis of data from the the FAP Erlotinib-Sulindac Trial (FAPEST) trial examines the effect of sulindac and erlotinib on colorectal adenoma formation and regression in patients with familial adenomatous polyposis.
from Cancer via ola Kala on Inoreader https://ift.tt/2nU5KNR
via IFTTT
Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου